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Abstract 
This article develops the sociology of hope and patient engagement by exploring how 
patients’ perceptions and actions are shaped by narratives of hope surrounding the clinical 
introduction of novel reproductive techniques. In 2015, after extensive public debates, the 
UK became the first country to legalise mitochondrial donation techniques aimed at 
preventing the transmission of inherited disorders. The article draws on the accounts of 
twenty-two women of reproductive age who are at risk of having a child with mitochondrial 
disease and would be the potential target of the techniques. We explore the extent to which 
our participants engaged with the public debates and how they accounted for their support of 
mitochondrial donation. We show that while the majority of our participants were in favour 
of legalisation, they did not necessarily wish to use the techniques themselves. We found that 
hope was multi-faceted, involving hope for self, hope for family and hope for society.  We 
conclude by considering the implications of hope narratives for patients and families and the 
important but potentially limited role that patients can play as advocates for technology.  
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Introduction  
Set in the context of public debates on ‘mitochondrial donation’1, this article develops the 
sociology of hope and patient engagement by exploring how patients’ perceptions, actions 
and identities are shaped by narratives of hope. Techniques of mitochondrial donation can 
prevent the transmission of maternally inherited mitochondrial disorders by conceiving an 
offspring with the genetic material of three people. These high-profile techniques were 
legalised in the UK in 2015 following extensive parliamentary debates, public consultations 
and meetings, institutional reviews and calls for evidence. There have been great expectations 
surrounding these techniques, which have been reflected and magnified through these 
debates. This article identifies these narratives of hope as ubiquitous, where the technology is 
framed in terms of potential treatment for people affected by mitochondrial disorders, and as 
associated with a powerful discourse of the prevention of suffering.  
We draw on interviews with women who are the imagined target of the techniques, women of 
reproductive age who are at risk of transmitting maternally inherited mitochondrial disease, 
and analyse how the hope narratives surrounding mitochondrial donation have been 
perceived and constructed by these women. Indeed, while much existing work has analysed 
the strategic uses of hope narratives at an institutional level, less attention has been given to 
what Petersen and Wilkinson call the ‘performativity of hope’ (2015: 117), that is, the ways 
these discourses are interpreted by patients and how they influence their views, identities and 
actions in practice. The question we address is why participants supported the legalisation of 
techniques, and indeed, invested their time and energy in the campaigns to legalise the 
techniques, when they might not be planning to use the technique themselves? Overall, we 
ask what does hope mean for patients in the context of emerging reproductive technologies 
and what are the implications of such powerful discourse?  
In this article, we first look at patients’ perceptions of mitochondrial donation and highlight 
the role of hope in patients’ support for their legalisation. Hope is multi-faceted and the 
reasons why participants supported the techniques are more complex than simply that they 
want to use the technologies themselves. We then describe how patients’ engagement in the 
debates has been shaped by this narrative of hope. We end with a discussion of the 
implications of hope narratives for families affected by mitochondrial disorders. Whereas 
previous conceptualisations of hope in relation to patient activism have highlighted resistance 
to the establishment, the way our participants have contributed to these narratives is by acting 
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as ‘advocates’ for the technology, a role which has more limited potential to influence the 
research or policy agenda.  
 
Legalising mitochondrial donation and the central feature of hope 
Mitochondria are small structures contained in our cells which provide energy. Mitochondrial 
disease can be caused by faults in the mitochondria, and can produce a wide range of 
symptoms including diabetes, epilepsy, muscle weakness, severe fatigue, heart problems and 
difficulties with balance and walking. Faults can be caused either by mutations of nuclear 
genes or mutations of mitochondrial genes, each leading to different patterns of inheritance. 
In this article we focus only on maternally inherited mitochondrial disease, the prevalence of 
which is difficult to estimate due to the wide range of clinical features, variable correlation 
between symptoms and genotype, and differences in how and when individuals seek medical 
care. The current estimated prevalence rate for maternally inherited mitochondrial disease is 
1 in 5,000 (Gorman et al. 2015). As mitochondrial genes are inherited through the female 
line, both sexes can be affected by maternally inherited mitochondrial disease but it is only 
females who are at risk of passing on those faults to her children. Many people can live 
without realising they have faults in their mitochondria, while for others it can be serious and 
sometimes fatal. There is no cure and treatment is limited. Scientists at the Wellcome Trust 
Centre for Mitochondrial Research in Newcastle, UK, have developed a specific IVF 
technique to avoid the inheritance of maternally inherited mitochondrial diseases involving 
cell reconstruction using part of a donated egg. The major implication of this technique is that 
the resulting baby would be born with nuclear genes from the intending mother and father, 
but their (healthy) mitochondria would come from the donor.  
The technique is controversial mainly because the mitochondria genes from the egg donor 
would be inherited by future generations. This is therefore considered a germ line technology, 
which had been banned in the UK, and the law needed to be changed before the techniques 
could be used in practice. From 2012, there was an extensive process of consultations, 
debates in the houses of parliament, and safety reviews to explore the implications of 
legalising mitochondrial donation (Dimond 2014). The consultations invited contributions 
from publics and patients, and concluded that the techniques were broadly ethical (Nuffield 
Council on Bioethics 2012), that there was general support for the technique (Department of 
Health 2014) and that the science was ‘not unsafe’ (HFEA 2014). The law was brought into 
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force towards the end of 2015 (HFEA 2015b) and by the end of 2016, clinics were able to 
apply for a licence if they could demonstrate expert use of the technology. At the time of 
writing, Newcastle is so far the only UK clinic licenced to offer the procedure to patients.  
As a novel technology, the debates about mitochondrial donation related to several broad 
concerns including safety and ethical implications. But while these issues were acknowledged 
and explored at length, the potential benefit to patients was rarely questioned (Herbrand 
2017). Instead, the mitochondrial debates could be characterised by a dominant and enduring 
narrative of hope about the perceived needs of patients. A key part of this narrative was the 
presentation of mitochondrial disease as being serious or fatal, and of the suffering of 
patients. Both the debates in the House of Commons and House of Lords for example opened 
with the same statement about the potential benefits to patients:  
The techniques provided for by these regulations offer the only hope for some women 
who carry the disease to have healthy, genetically related children who will not suffer 
from the devastating and often fatal consequences of serious mitochondrial disease. 
(Jane Ellison, House of Commons debate 3 February 2015, Column 160)  
Throughout the debates, mitochondrial donation was framed in two main ways. First of all, 
mitochondrial donation was positioned as a viable, essential and desired technological 
solution and the ‘only hope’ for some women. Within this framing, there was little room for 
more clearly defining the category of who might be ‘at risk’, and providing a more nuanced 
account of the role of reproductive technology in their reproductive decision-making 
processes. Secondly, mitochondrial donation was positioned as a technology that would 
prevent suffering, and the suffering of children in particular. As Buchbinder and 
Timmermans (2014) have highlighted, the mobilisation of suffering can become an important 
part of political projects because of the emotional response it gains from policy makers. 
Accounts which feature the ‘desperateness’ of those who could potentially benefit from 
scientific progress have persuasive appeal (Franklin 1997). Many of the consultation reports 
and debates highlighted the patient perspective, often focusing on emotional stories about 
children who have short but difficult lives affected by mitochondrial disease. This emphasis 
accorded with the activities of the patient group who rose to prominence during the time of 
the debates. This patient group mostly represented families whose children were affected by 
mitochondrial disease and presented a particular kind of ‘patient’ experience – healthy 
women with seriously ill children. People affected by mitochondrial disorders were 
represented as a homogenous group, sharing a common experience of illness, suffering and 
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loss, and this informed dominant representations in media coverage, reports and subsequent 
debates. The power of these particular narratives in the public sphere has led to a narrow 
representation of patient experiences and has informed a limited vision of what mitochondrial 
disease means to those affected.  
 
Narratives of hope  
In recent years, the concept of ‘hope’ has often been employed in studies of health, illness 
and medicine. Hope is framed as an ‘emotional attitude’ (Simpson 2004: 428) which ‘orients 
the hoper towards particular phenomena (in the future)’ (Brown et al. 2015: 209). However, 
as Petersen and Wilkinson (2015) point out, hope is still too often addressed and understood 
at an individual level and from a medical or psychological perspective as a valued attitude to 
promote adherence to treatment regimes or to adapt to changes in health and illness 
management. Instead, Petersen and Wilkinson (2015: 114) encourage the development of the 
sociology of hope by ‘critically questioning the values incorporated within the social 
representation of hope as a positive attribute of health or as a goal of medicine'.   
In this respect, a small but growing body of sociological work has highlighted the 
institutional and cultural processes generating and disseminating hope, as well as their 
political or economic consequences (Brown 2005, Good 2001, Novas 2006). In particular, 
social scientists have examined how ‘rhetorics of hope’ are deployed and mobilised, often 
strategically, to legitimize and promote new research, technologies or treatments, as well as 
to attract support or funding (Martin et al. 2008, Mulkay 1993, Petersen and Seear 2011). 
These rhetorics of hope reflect an ‘implicit model of scientific progress’ (Mulkay 1993: 725). 
Not only does it present scientific innovations and more broadly the relationship between 
science and society in a positive light, but it implies a forward looking attitude towards future 
potential benefits which have yet to be realised (Brown 2003, Moreira and Palladino 2005). 
Social scientists have also looked at how hope works in practice, especially how patient 
experiences can be affected by hope in their everyday life (Brown et al. 2015, Eliott and 
Olver 2007). Hope is particularly prominent in the field of reproduction when the desire to 
have a child, and of the new life which may come with it, generates and justifies high 
expectations and investments. For individuals facing difficulties to conceive or the risk of 
transmitting genetic disorders, the technologisation of reproduction conveys the promise of 
desired and healthy babies, and more broadly the promise of restoring a ‘natural order’ and 
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life expectations that have been disrupted (Throsby 2004). Reproductive technologies, such 
as IVF (in vitro fertilisation), PGD (pre-implantation genetic diagnosis), gamete donation or 
egg freezing  thus become ‘hope technologies’ (Franklin 1997: 176, Franklin and Roberts 
2006): they keep hope alive against the odds and give patients the possibility to act on their 
situation. However, the hope generated by scientific and technological progress may confront 
intending parents with frustrating and disappointing ‘corpo-realities’ (Brown 2005), when 
bodies fail to comply with technological means. But as Szweczuk (2012) points out, it is 
precisely the uncertainty regarding the successful outcome of these technologies that enables 
hope to appear and remain. Franklin describes how women and couples trying to have a child 
using IVF therefore need to carefully ‘manage’ their hope, whilst caught in cycles of 
optimism and disappointment. It requires ‘balancing sufficient measure of hope against a 
realistic appraisal of the likelihood of failure’ (1997: 158), in order to be able to continue and 
cope with this emotionally laden procedure (Haimes 2013). Ultimately, attempting 
conception with assisted reproductive technologies appears compelling for many individuals 
as it enables them to ‘exhaust’ this hope and prevent future possible regret (Tymstra 1989).  
Investment in hope can also play a crucial role in generating actions at a more collective 
level. Novas argues that the hope of cure or treatment plays a crucial role in the formation of 
patient activism. The ‘political economy of hope’ (Novas 2006: 289) contributes to a 
transformation of biomedical research and the bioeconomy, in particular through the 
regulation of research trials and commercialisation of donated tissues. While the notion of 
‘political economy of hope’ was initially used to conceptualise the hope produced within the 
clinical encounter by the clinician, particularly when disclosing a cancer diagnosis (Good et 
al., 1990), Novas emphasised the economic and political investment in hope and the 
mobilisation of patient activities. Within this model of hope, patienthood is conferred with 
agency. Patients are recognised as experts and activists in medical and scientific spaces 
beyond the clinical encounter, and play key stakeholder roles.  
However, as many authors have shown, there are difficulties associated with mobilising hope. 
There can be a lag between the hope associated with the development of treatments and cure, 
and their realisation as clinically applicable and available to patients (Brown 2003, Stockdale 
1999). There is also the ‘danger’ of risks associated with new technologies. Petersen and 
Wilkinson highlight how the ‘‘the power of hope’ has the potential to mobilize diverse 
constituencies and to engender commitment to clinically unproven treatments or care regimes 
that may, in time, be shown to have no benefit and may even be dangerous’ (2015: 116). As 
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they also point out, understanding hope only in terms of whether hope is ‘realistic’ or ‘false’ 
prevents us moving forward to an understanding of the ‘politics of hope’. In accord with 
Petersen and Wilkinson, we have directed our attention to the politics underlying 
mitochondrial donation and its debates as particular ‘hope-promoting’ practices. Indeed, 
examining the ‘hype’ around mitochondrial donation is important because the debate engaged 
so many people and appeared applicable to so many, despite mitochondrial disease being a 
rare disease, and those able to take up reproductive options being an even smaller sub group. 
Whereas health professionals can play an important role in shaping patients’ responses 
towards hope (Simpson 2004), our emphasis is the public and political nature of the 
mitochondrial debates which enabled patients to be positioned as contributors at one 
particular moment in the developmental trajectory of a reproductive technique.  
 
 
Methods  
This article draws on data collected for two separate research projects focusing on the 
experiences of women affected by mitochondrial disease. The projects’ aims were twofold: 
firstly, to understand individual and familial experiences of diagnosis and disease and 
secondly, to explore their perspectives regarding reproduction options, in particular about the 
IVF techniques involving mitochondrial donation. For both projects, in-depth interviews were 
conducted mainly with women of reproductive age (classified in both studies as 18 – 45 
years) who were at risk of transmitting mitochondrial disorders to their children.   
Project 1 involved interviews with 42 people. Twenty-eight of them were women affected by 
mitochondrial disorders, either because they were carrying mitochondrial mutations and 
might develop the disease (n~11), or because their child was affected by the disease (n~17)
2
. 
Fourteen family members were also interviewed, including partners, mothers and sisters. 
Patients were recruited through the national patient cohort database held at Newcastle 
University and a national support group, and ethics approval was granted from De Montfort 
University and the London NRES Committee. Project 2 involved interviews with 31 people. 
Eleven of whom were women of reproductive age who had been diagnosed with maternally 
inherited mitochondrial disease, 11 women were older (over 45 years old) and were 
diagnosed with maternally inherited mitochondrial disease, and 9 were partners or male 
relatives. Patients were recruited through the national patient cohort database held at 
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Newcastle University and ethics approval was granted from the North Scotland NHS 
Research Ethics Committee. Only the interviews conducted with 22 women of reproductive 
age who carry maternally inherited mitochondrial mutations are reported here, i.e. 11 from 
each project who were under 45 and at risk of transmitting mitochondrial mutations). The 
ages of the women ranged between 19 and 44 and they all lived in the UK.. The women came 
from diverse social and economic backgrounds, presented various professional and family 
situations and ten participants had children at the time of the interview, including three who 
had their children after being diagnosed with mitochondrial disorders. 
Although the women presented different symptoms and health conditions, ranging from no 
symptoms to moderate symptoms threatening life quality, they shared the risk of having a 
child with mitochondrial disease. These women are potential future users of mitochondrial 
donation and have been presented through the debates as ‘patients’ in a broad sense. They 
also either identify as ‘patients’ with mitochondrial disease, or consider themselves, or their 
children (or future children) as being at risk of developing mitochondrial disease. They 
therefore have, in principle, the same reproductive options if they want to have a child: have a 
child without assistance with a risk of transmitting the disorder, adoption, egg donation, 
prenatal diagnosis, pre-implantation genetic diagnosis, and possibly, mitochondrial donation 
(Richardson et al. 2015). In this article, we only discuss participants’ views on mitochondrial 
donation and not their responses to other available reproductive options. 
Most of the interviews took place in the respondent’s own home, and lasted between 45 
minutes and 2 hours. The interviews were audio recorded and transcribed. Data were 
analysed using thematic analysis (Braun and Clarke 2006), which involved reading the 
transcripts and identifying key themes. Once analysis was conducted on each data set by the 
corresponding author, the authors met to talk about the themes which were prominent in each 
data set and where comparisons could be made. We shared and re-analysed together the 
relevant parts of the anonymised transcripts. The key themes which are discussed in this 
article, including expressions of support for mitochondrial donation and contributions to the 
debates were prominent across both data sets.   
With our combined findings, this constitutes the largest sample of women carrying 
mitochondrial mutations to be studied from a qualitative perspective, as well as the first 
sociological analysis focusing on the experiences of these women following legalisation of 
mitochondrial donation in the UK. 
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Supporting mitochondrial donation 
Amongst our participants, only three women did not overtly support the legalisation of the 
techniques. Two of the women took this position because they suggested that they did not 
know about the techniques and the other for religious concerns. The rest of our participants 
explained at length why they supported the legalisation of the techniques. However, they did 
not necessarily support mitochondrial donation because they wanted to use the techniques 
themselves. Some participants were not planning to have children, or any more children, 
sometimes because they felt their own health threatened their ability to look after a family. 
Nonetheless, whether or not women have already had families, were planning to start a 
family or have decided against having children, most participants expressed that they 
supported the techniques. Their stories highlight the various facets of hope which were 
represented by the techniques. We have grouped and developed these under the following 
themes: hope for self, hope for the family and hope for society.  
 
Hope for self: the potential to have healthy children 
For a minority of our participants, the techniques represented a very real opportunity to 
improve their own chances to have unaffected children. The techniques and their legalisation 
were perceived as part of their own journey. Beth [C22]
3
, who was in her early twenties and 
in a relationship for 3 years, explained why she would want to use the techniques:   
Well I don’t want to have a child that has any [faulty] mitochondria at all, just 
because I think it would be hard for me showing symptoms and things like that. I 
think it would be hard for me to then deal with a child that has the same as what I 
have, you know, with my energy levels and things like that it would be really hard for 
me to cope. I wouldn’t want to have to go through what we went through with Tom 
[her brother who died from MT disorders] again and I just think it would be...  I just 
would like a healthy baby (laughs).  
This woman’s account is embedded in her experience of living with the increasing signs of 
the disease. Although she works full time, she was beginning to experience extreme tiredness 
and much lower ‘energy levels’. She was interested in mitochondrial donation as it was very 
important to her to have a genetically related child later on. However, she expressed that she 
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definitely did not want to pass on the disorder and allow her child to go through what she 
herself experienced. She also did not think she would be able physically to cope with a child 
who was disabled, as she often felt weak and could see how much energy it required when 
her mother had to take care of her brother who was affected by mitochondrial disorder and 
died a few years earlier. Mitochondrial donation was therefore a means to avoid reproducing 
the still deep and traumatising experience it had been for her family. 
Another woman who saw the techniques as allowing her to have a healthy child was Alice 
[C13], late twenties, who was interviewed with her boyfriend. After her mother was 
diagnosed with mitochondrial disorder, she herself was tested for the mutation and learnt that 
she carried the faulty gene, though she had not experienced any symptoms at the time of the 
interview: 
In a way, with everything being so doom and gloom about the diagnosis, it seemed 
like a bit of a ray of light at the end of the tunnel. Because it would give us the 
opportunity to live a normalish life, even though we are a family affected by 
mitochondrial disease, we will still be able to have a family and be normal. Knowing 
that our babies [are] not going to be affected by it.   
For Alice, mitochondrial donation represented an opportunity for her to have a healthy child 
and therefore ‘live a normalish life’ in the context of a severe illness which had affected other 
members of her family. Whereas Beth’s account was primarily contextualised within the 
experience of degenerative disease and Alice was not currently displaying any symptoms of 
disease, they both supported the legalisation of mitochondrial disease because it represented 
an opportunity for them to have healthy biologically-related children. Thus mitochondrial 
donation was viewed as a viable technology, whether or not the woman was experiencing 
symptoms of mitochondrial disease.  
While some respondents who expressed support for the techniques did so because they 
believed they were in a position to use them, this group of women were in a minority. They 
were the younger participants of our sample who had not yet children. For the majority of our 
respondents, there was not such a direct link between supporting the techniques and wishing 
to, or being in a position to use the techniques themselves.  
Hope for the family: the potential for daughters to have healthy children 
Respondents spoke about the future benefits of mitochondrial donation when their daughters 
would be preparing to have children. This was the case for Helen [R16], who was in her early 
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forties and had diabetes and deafness. She was diagnosed with mitochondrial disease when 
she went for genetic testing with her mother and sister, after they developed diabetes. By that 
stage, she had had a son and daughter. Her daughter was 10 years old and appeared healthy at 
the time of the interview. Speaking about mitochondrial donation, she explained:  
It’s not going to affect me in any way. It’s more important for me because it’s going 
to affect me directly in terms of my daughter, it’s going to affect her very directly. At 
the end of the day the reproductive thing offers me nothing, it offers my daughter 
hope, it doesn’t offer me anything.  
Another participant, Julie [R10], also said she supported the techniques because it offered 
hope for her two daughters who were both born after her diagnosis. Julie was in her early 
forties, and was diagnosed about five years ago through her hearing problems. She said that 
her mother had not yet been diagnosed, although was thinking about it because they had a 
large extended family and that information might be relevant to others in the family. At the 
time of the interview her two daughters were in their early teenage years:  
So I've definitely taken more interest in [the debates about mitochondrial donation] 
because I know that could affect both of them two as they go along, sort of thing. And 
hopefully, by the time they are at the age for having children, it'll be all sorted and it's 
an option for them. I mean, then that will be their decision, won't it, but it's there for 
them at least to have, isn't it?’ 
Another woman, Sally [C23] explained that if she could, she would like to use mitochondrial 
donation later on to have children. She was in her early twenties, did not have any children 
yet and although she felt healthy, two of her siblings were suffering quite seriously from 
mitochondrial disease. Her concern was not so much to avoid the transmission of the disorder 
but rather to guarantee reproductive health to her children. To her, the techniques represented 
an opportunity to protect her future children from carrying the psychological burden and the 
medical risk of transmitting the disorder to future generations:  
I don’t want my child to have to think how they’re going to have a baby because they 
might pass it on to their children, like it’s not a nice thing to think about. So I don’t 
want to conceive naturally due to that reason only. Like my levels at all don’t bother 
me, because I know that I’m not affected, but I just don’t want it to carry on for 
generations, so I’d much rather it just stop here and be done with. 
Question: So you would be willing to use the technique as well? 
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Yes, just because I wouldn’t want to pass it on and for a child to grow up with those 
worries about am I going to get worse? Is it going to be ok? Am I going to pass it on 
to my child? I just think it would be easier.  
Sally provides an interesting account because, like many other respondents, she focuses on 
several aspects of risks. She not only discusses her reproductive choice in terms of the child 
inheriting the condition but importantly, she also describes her concern about passing on 
reproductive risk to her own child. What unites the woman and her future (female) child is 
that both would experience the possibility of making potentially difficult reproductive 
choices. It also suggests that parents are not just concerned about the child’s genetic risk 
more than their own health (McAllister et al. 2007), but also about the child’s future 
reproductive risk. 
The patients in our sample presented various reasons as to why their children (or future 
children) would benefit from mitochondrial donation, including offering an additional 
reproductive option and allowing daughters to have children without fear of having the 
disease. What is interesting about this position is that several of our participants themselves 
were not diagnosed until after they had had children, and therefore are projecting a particular 
future for their daughters, where risk is known and is a key factor in reproductive decision 
making. This suggests how our participants’ projections for hope in the future are based on 
their reflections about their own experience of having children but combined with the new 
knowledge of what it means to live with illness or reproductive risk. 
Hope for society: supporting opportunity for others  
The previous sections have highlighted how some participants expressed their support for 
mitochondrial donation because of the direct benefits to themselves or their families. But 
overall, the majority of our respondents remained committed to the idea that mitochondrial 
donation should be made legal and should be made available. In doing so, they highlighted 
the wider benefits of such technologies in terms of supporting the reproductive choices of 
other women, and for society. 
It was clear that participants recognised the need to support the wishes of others to have the 
opportunity to have a healthy child, for example, those who might have experienced the 
heartbreak of having a child die because of mitochondrial disease. For instance, Wendy [C1] 
did not know whether mitochondrial donation would be legalised and available in time for 
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her to use it in order to have a family as she was already in her late thirties. In any case, she 
thought it should be authorised as it would help other people and give them hope:  
From what I have read, I think it would be a good thing for future people to have their 
own child. They probably feel like me because of the difficulty of carrying the 
mitochondrial disease, it does give people hope out there. […] It prevents that fault 
being passed down to another child in the future. To me, it could decrease the amount 
of people that are actually ending up with the mitochondrial disease in the future.  
This was also the case for Ruth [R22], who is in her late 30’s and was diagnosed about 7 
years previously. She is mainly affected by migraines and tiredness, and is the only member 
of her family to have been diagnosed, and the only member to show symptoms. Although she 
does not have children herself, she accounted for her support for the techniques by 
highlighting the suffering of parents who risk losing their children to the disease: 
I just think if you can [stop] parents going through losing children or children having 
this disease, then I’m all for it.  
Overall, these accounts illustrate the ubiquity of hope in patients’ perceptions of 
mitochondrial donation. Participants supported the legalisation of mitochondrial donation for 
a number of reasons, including for personal reasons. But supporting the technologies on 
behalf of others presents a different account in terms of the narrative of hope. It provides a 
reminder as to why we need to pay attention to the way in which technologies are represented 
in the public arena. Presenting mitochondrial donation as a technology which can stop the 
suffering of children (in particular) remains a dominant trope, even for those who were 
without symptoms themselves and those who experienced mitochondrial disease as adult 
onset.    
 
How is patient agency mobilised by hope? 
Not only were most women we interviewed in favour of mitochondrial donation but most of 
them also actively supported them by becoming involved in the related debates. Engagement 
took very different forms: following the debates on television or radio and reading 
newspapers; asking friends to text the result of the votes; writing to their MP and sometimes 
meeting with him or her; attending public meetings as a participants or speakers; attending 
Parliament during the voting process; speaking to the media about their experience of living 
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with mitochondrial disease and about their views on mitochondrial donation; responding to 
calls for evidence; taking part in social events to collect funds, offering to take part in 
research, including for example, and at the extreme end, offering their eggs for donation for 
research purposes. 
One of the key ways that patients could contribute to the campaign, which patients were 
actively encouraged to do, was to make contact with their MP before the vote in the House of 
Commons, either by meeting and talking to MPs during special sessions organised by the 
support group before the key debates at the Parliament, or by sending pre-printed support 
letters prepared by the clinic to their MP. One participant, Anna [R14], was interviewed with 
her partner and spoke at length about how she had contributed to the debates, mainly by 
contacting her MP to ask for their support. Anna was diagnosed after her mother was 
diagnosed – her mother had become ill quite suddenly, and her diagnosis therefore came as a 
shock to her and her siblings. Anna did not have children but was currently investigating 
different possibilities through assisted reproduction: 
 [The director of a specialist mitochondrial disease clinic] sent us a letter that we could 
forward on. And actually, it was a well written letter and it wasn't saying ‘This is the 
best thing ever’. It was ‘Please support the debate’.  
The accounts of our respondents who actively contributed to the debates highlight that the 
work of the engaged patient does not just entail making contact with their MP. Many 
respondents followed up whether or not the MP voted in favour. One participant, Jackie [R8], 
who was in her late thirties, and was diagnosed five years previously after suffering extreme 
tiredness, describes the extent to which she went to make contact with her MP: 
I spoke to my MP about it. She voted for it. I spoke to her the night before the vote, 
because I left messages and we were due to meet but the meeting was after the vote. 
So I called them Monday morning and I said, ‘Look, there’s no point in us meeting 
later in the week if the vote is tomorrow, can she call me today?’ And she didn't know 
anything about me. So she called me on Monday at nine o’clock in the evening, 
before the vote. And she [her MP] said she was inclining to vote for it but after talking 
to me she was determined to vote for it.  
Two of our participants who were asymptomatic also actively engaged by attending the 
public meetings which took place at Parliament, and telling the audience how important it 
was for them to access mitochondrial donation in order to have healthy children. Moreover, 
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several participants spoke to the media to tell their stories and to manifest their support to the 
techniques. 
What unites all these accounts and the diverse activities of patients is that patients were very 
much emotionally engaged. One of our participants [C9], after following the vote in the 
House of Lords, told us that she ‘started crying that day, I was so happy. It’s a good thing’. 
Aligned with the opportunity to provide the patient voice to the debates, is the fact that 
overall their contributions were highly valued. Patients were able to be presented as having 
‘direct experience’ of the disorders and being potential ‘users’ of the techniques, and as such, 
they provided evidence of the desirability and essentiality of mitochondrial donation. 
Engaging in the debates has been empowering for some participants, as was the case for 
Alice [C13] mentioned earlier:  
He [the director of a specialist mitochondrial disease clinic] said [the techniques] will 
go through Parliament shortly but he didn’t sort of try and put our hopes up and say 
‘well this technique will be available for you’. He just said this is something like ‘we 
have been working on and it is going to go through Parliament shortly’. And that was 
how it was left until he contacted us and we thought ‘oh god it’s come round’. And 
we were glad in a way to be part of it thinking well this is potentially something that 
is going to affect our future. And if we can help in any way then we will so we were 
honoured, well I was, that he asked us to help because it’s sort of being part of history 
in a way, isn’t it.  
Being part of the debates had important implications for Alice, particularly because it allowed 
her to be ‘part of history’. For Katie [C9], a young single woman, the debates presented a 
public stage as an opportunity to ‘come out’ and embrace her diagnosis and her experience of 
illness. She has started to develop several mild to severe symptoms over the past few years. 
She wants to have children later on, though she knows her condition is worsening and she is 
worried about the extent to which it will get. She does not want to pass on the disease, so she 
thought first about adoption, but then she became interested in mitochondrial donation. After 
hearing about the debates, she told her story to the media, which was the first time she openly 
talked about her experience, even to friends:   
I had some school friends messaging me on Facebook saying that it was really 
admirable of me to come with my story. When I was in school they didn’t even know, 
the teachers didn’t know, because I would be very slow in Physical Education, I 
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would get very tired I wasn’t really like everybody else. But now this has all come 
out, it’s probably because I am mitochondrial that’s why I was getting really tired. But 
it’s all come out now and I think they do understand a bit more about my condition 
and hearing. Not many of my friends know much about it. […]  
Question: And you were not afraid that your friends and everyone would know then 
that you had a disorder? 
I wasn’t afraid I thought everyone should know now. […] 
I don’t mind telling people about it, so they have more understanding about how I feel 
and how it’s affecting me.   
Whatever the nature and extent of their involvement, it is important to emphasise that the 
mitochondrial donation debates presented the first opportunity for most participants to 
become involved in activities on a public stage and patients took up the opportunity with 
enthusiasm and passion. Thus the mitochondrial donation debates remind us of the 
importance of the political context when we are examining hope (Novas 2006). The 
mitochondrial debates follow a format which is increasingly familiar when discussing novel 
technologies, where the technology is framed as what patients want, and the patient 
experience is showcased as support. Indeed, we have found that patients have widely 
supported the techniques, and taken up the opportunity to express their support. But it is 
important to note, in the context of examining patient activities around the central theme of 
hope, that these opportunities to speak in favour of the technology and its legalisation arose 
from the nature of the debates (for example, the numerous calls for evidence and media 
interest), rather than being identified as opportunities by the patients themselves. Mobilised 
by the clinics and the support groups, patients in the mitochondrial debates were framed as 
users and as drivers of the technology, but they were invited to take up this position rather 
than design the role for themselves. 
Discussion 
The debates about mitochondrial donation were dominated by the culturally powerful 
narrative of hope, bolstered by stories about patients and by the mobilisation of patients 
themselves. Patient experiences became important evidence in support of the legalisation of 
the techniques, and patients enthusiastically took up the opportunities to contribute to the 
debates. Patients (or parents of an ill child) were given a high status as experts within the 
debates. They were allocated the opportunity for their voices to be heard, sometimes over 
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others, because of their status as potential users. Whether speaking for themselves or spoken 
for on behalf of others, patients ultimately played a key role in the mitochondrial debates 
because their stories were persuasive about the difficulties of living with mitochondrial 
disease, and by association, of the value of mitochondrial donation and its legalisation. 
But we have found that the mitochondrial debates were limited in scope, particularly around 
how the patient experience was presented. Mitochondrial disease is a complex condition, 
highly variable, and for many people will be late onset. The representation of mitochondrial 
disease as only affecting seriously ill children does not do justice to the experiences of many 
of those who are currently living with mitochondrial disease as adults. In addition, 
mitochondrial donation was widely represented as a technological solution, with little 
discussion in the debates about how women with mitochondrial disease make reproductive 
decisions and might negotiate reproductive options. But importantly, we found that our 
participants did not express concerns about these discrepancies. Instead, the majority of them 
expressed support for mitochondrial donation and their accounts suggested the extent to 
which they were willing to emotionally engage in the campaign to legalise the technology.  
Our examples show that participants supported the techniques for a number of reasons. For 
them, hope is complex and multifaceted, involving hope for self, hope for family and hope 
for society. Some of our participants invested in the technology because they believed that 
the techniques could be personally beneficial. Mitochondrial donation appeared as an 
important route for them to have a child in the near future. Their accounts reflected an 
immediacy associated with the experience of mitochondrial disease, and their stories in the 
most part reflected those in the media accounts of women who have either suffered the loss of 
a child or have a severely ill child. In this context, participants felt that the techniques would 
provide them with the opportunity to have a healthy child. In contrast to their hope for self, 
another kind of hope emerged as prominent through our research. This is where women 
expressed the hope and expectation that their own daughters would be able to use the 
technology, and allow them the option of having a health child without fear of passing on the 
disease. Hope for family represents a move away from personal experiences of health and 
reproductive options, and instead focuses on the (future) reproductive options of children or 
future children. In comparison to the dominant narrative that women will use mitochondrial 
donation to have their own healthy genetically related baby, the nuanced reasons as to why 
women might support the legalisation of a reproductive technology are much less represented 
within media accounts. It also represents an important field for future research about how and 
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when families communicate about reproductive risk to their children. Finally, many of our 
participants expressed their support for the techniques because of the benefit they could bring 
to other families, who might be more seriously affected and might have had severely ill 
children. In this case, even when the stories which appeared in the media or public accounts 
did not represent their own experiences, our participants supported the techniques by 
empathy for other people.  
Despite their various acts of engagement, it is important to highlight that none of our 
participants could be considered as ‘activists’ fighting against the institution in way that 
Taussig and colleagues (2003) amongst others have described. ‘Patients’, understood in a 
broad sense, were allocated a space to become involved and detail their positions, rather than 
having to fight for the right to speak. In this respect our work contrasts with what is known or 
assumed about patient activities in the context of the political economy. Novas highlights 
how ‘patient organisations not only challenge the authority of biomedical research but also 
help to transform the contexts in which it takes place’ (2006: 291). The mitochondrial debates 
provide an example of how the political activities of patients do not necessarily challenge 
authority. Instead, the patient role became more like that of an ‘advocate’, or as a witness, 
explaining the daily implications of their experiences of being affected by mitochondrial 
disease, and providing personal testimony as to how and why legalisation is essential. This 
suggests a more limited role for patients in influencing the research agenda. 
According to Novas (2006: 292): 
Science constitutes one horizon along which potential futures are constructed. By 
engaging with scientists and advocating particular forms of research, treatment 
modalities and forms of regulation, patients’ organizations are actively involved in 
shaping particular futures to the exclusion of others.  
 The potential for patient organisations’ activity to exclude other futures is an important 
aspect to apply to the mitochondria example. The involvement of patients has helped to shape 
the biomedical future in the case of mitochondrial disease, but it might not be a future that 
patients would choose if they were allowed greater political power. There is no cure for 
mitochondrial disease and treatment is limited because of its genetic complexity (Rai et al. 
2015). Even so, at the time of the mitochondrial donation debates, the possibilities for 
developing treatments had not emerged as a political issue, and we have not yet witnessed 
large scale activities, requiring such extensive patient involvement, around the development 
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of a cure for mitochondrial disease for those living with disease rather than preventing the ill-
health of future others.  
The case of mitochondrial donation suggests that while patients have wide opportunities for 
engagement, they have a narrow range of political options. Their options were shaped by the 
technologies currently being developed (reproduction rather than treatment) and the political 
will of the scientists and clinicians who are developing them. Patient power, in the case of 
mitochondrial donation, was restricted to public engagement to support the legalisation of 
one technology which has limited potential to change patients’ current lives.  
Following the debates, it seems that the trajectories of the clinical team, and the hopes of 
patients and families, were only momentary aligned, and for a particular purpose.
 
While the 
debates gave patients the opportunity to have their voice heard and to become publically 
engaged by supporting the legalisation of the techniques, for most of our participants this 
involvement was short term. One reason for this is that campaign activities stopped quite 
abruptly after the legalisation of mitochondrial donation. Indeed, the adoption of the law in 
February 2015 was followed by a long licencing process which was only completed in 
October 2016. During this period, the support group was not required to be so politically 
visible while they waited for the procedures to be put in place. 
Alongside the legalisation of mitochondrial donation, the mitochondrial debates have no 
doubt increased public awareness and raised the profile of a rare genetic disease. But it is 
important to remember the social significance of particular representations of disease and 
technological solutions. The dominant representation of a disease that causes child suffering 
and early death did not appear to distress our participants, but it might have implications for 
others living as adults with the disease and their family members. In addition, while 
mitochondrial donation was represented as a technology that all patients could use, it is only 
suitable for patients with maternally inherited mitochondrial disease which would rule out a 
large proportion of the patient population with different kinds of mitochondrial disease (such 
as those with recessive or dominant inheritance patterns). And of course, it would not be 
accessible to women who do not know that they are at risk of having a child with the disease. 
However, with the recent licencing of the techniques, it was also not clear whether some in 
our sample would be able to access the techniques, even  though they may think so. The new 
regulation will indeed include a clinical judgement about their risk of having a child with the 
condition and the potential severity of the future child’s symptoms. In short, it must be 
assumed under current legislation and licencing procedures that the diagnosis of maternally 
20 
 
inherited mitochondrial disease does not necessarily mean that someone will legally be able 
to use the techniques. This suggests that there is potential for some to experience a ‘false 
sense of hope’ (Stockdale 1999: 87). This article contributes to the sociological 
understanding of hope by highlighting how patient voices were welcomed and valued within 
a highly public and politicised debate. But by identifying how patients played the role of 
advocates of the technology, we also highlight the potential vulnerability of patients. Our 
study provides empirical evidence of the tensions inherent in public debates and we 
encourage researchers to continue to question how patient voices are registered and enrolled 
as imagined users or advocates of future technologies.  
If the combination of hopeful technologies with the power and currency of patient support is 
to become the norm for public engagement strategies around the introduction of novel 
biotechnologies (as is starting to be the case with genome editing), then our article provides 
evidence that we need to think more carefully about patient contributions. We also ask 
therefore for social scientists to think about how future visions are constructed and how 
patient activities are directed towards specific agendas. Who is directing, and who or what is 
excluded, particularly when technologies are not going to improve the health of those living 
with disease, from the political economy of hope is worthy of further research.  
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Notes 
 1. We use the term mitochondrial donation throughout this article as this was the main term 
used in UK institutional reviews (Department of Health, 2014; HFEA, 2015a), but we 
acknowledge that there is divergent views over the accuracy of the term (see for example, 
Haimes and Taylor 2017, Dimond and Stephens 2017). 
2. Most of these children’s disorders were caused by nuclear defects. This means that their 
mothers are not suitable to use mitochondrial donation. 
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3. We have used pseudonyms to refer to our participants, in addition to their reference 
number. ‘C’ refers to project 1 and ‘R’ to project 2. 
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